Gilead to sell Viread at cost to 68 developing nations
BY Advocate.com Editors
April 09 2003 12:00 AM ET
Gilead Sciences announced Friday that the company will sell its HIV nucleotide reverse transcriptase inhibitor Viread at cost, approximately one tenth of its retail price, in 68 developing nations, the Los Angeles Times reports. The drug will be available for about $475 per person per year in every African nation as well as 15 other poor countries. Treatment programs in those countries can apply to purchase Viread at cost only, by mail or by fax. The company will choose eligible applications based on their ability to sustain an effective treatment program, adequately prescribe and monitor patients, and store the drug appropriately. The company also plans to manufacture the drug in a different color than it is sold in developing nations to prevent the cheaper medication from being reimported and sold in developed countries.
- Why These Four Justices Rejected Marriage Equality
- WATCH: Mississippi Clerk Refuses to Wed Gay Couples, Quits After 24 Years
- Girl Scouts Return $100K When Donor Demands It 'Not Be Used' For Trans Girls
- Why Is the Duggar Family Paying the Cops Investigating Them?
- George Takei Takes on Clarence Thomas and Donald Trump (and Wins!)
- Girl Scouts Raise $100,000 in One Day After Dropping Transphobic Donor